• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Effectiveness of School-Based Influenza Vaccination

Anne

Senior Moderator
v2_orig_art.gif
<table border="0" cellpadding="0" cellspacing="0" width="640"> <tbody><tr> <td nowrap="nowrap" valign="top">[FONT=arial,helvetica][SIZE=-1]Previous[/SIZE][/FONT]</td> <td align="center" valign="top"> <table border="0" cellpadding="0" cellspacing="0"> <tbody><tr><th align="right" nowrap="nowrap" valign="top">Volume 355:2523-2532</th> <td nowrap="nowrap">
spacer.gif
</td> <th nowrap="nowrap" valign="top">December 14, 2006</th> <td nowrap="nowrap">
spacer.gif
</td> <th align="left" nowrap="nowrap" valign="top">Number 24</th> </tr></tbody></table></td> <td align="right" nowrap="nowrap" valign="top">[FONT=arial,helvetica][SIZE=-1]Next[/SIZE][/FONT]</td> </tr> </tbody></table>​

[FONT=Arial, Helvetica, sans-serif][SIZE=+2]Effectiveness of School-Based Influenza Vaccination[/SIZE][/FONT]
<center>[SIZE=+1] James C. King, Jr., M.D., Jeffrey J. Stoddard, M.D., Manjusha J. Gaglani, M.B., B.S., Kristine A. Moore, M.D., M.P.H., Laurence Magder, Ph.D., Elizabeth McClure, M.D., M.P.H., Judith D. Rubin, M.D., M.P.H., Janet A. Englund, M.D., and Kathleen Neuzil, M.D., M.P.H. [/SIZE]</center>[FONT=arial, helvetica][SIZE=+1]ABSTRACT[/SIZE][/FONT] [FONT=arial, helvetica] Background Vaccination of children in school is one strategy<sup> </sup>to reduce the spread of influenza in households and communities.<sup> </sup>[/FONT]
[FONT=arial, helvetica]Methods We identified 11 demographically similar clusters of<sup> </sup>elementary schools in four states, consisting of one school<sup> </sup>we assigned to participate in a vaccination program (intervention<sup> </sup>school) and one or two schools that did not participate (control<sup> </sup>schools). During a predicted week of peak influenza activity<sup> </sup>in each state, all households with children in intervention<sup> </sup>and control schools were surveyed regarding demographic characteristics,<sup> </sup>influenza vaccination, and outcomes of influenza-like illness<sup> </sup>during the previous 7 days.<sup> </sup>[/FONT]
[FONT=arial, helvetica]Results In all, 47% of students in intervention schools received<sup> </sup>live attenuated influenza vaccine. As compared with control-school<sup> </sup>households, intervention-school households had significantly<sup> </sup>fewer influenza-like symptoms and outcomes during the recall<sup> </sup>week. Paradoxically, intervention-school households (both children<sup> </sup>and adults) had higher rates of hospitalization per 100 persons<sup> </sup>than did control-school households. However, there was no difference<sup> </sup>in the overall hospitalization rates for children or adults<sup> </sup>in households with vaccinated children, as compared with those<sup> </sup>with unvaccinated children, regardless of study-group assignment.<sup> </sup>Rates of school absenteeism for any cause (based on school records)<sup> </sup>were not significantly different between intervention and control<sup> </sup>schools.<sup> </sup>[/FONT]
[FONT=arial, helvetica]Conclusions Most outcomes related to influenza-like illness<sup> </sup>were significantly lower in intervention-school households than<sup> </sup>in control-school households. (ClinicalTrials.gov number, NCT00192218<!-- HIGHWIRE EXLINK_ID="355:24:2523:1" VALUE="NCT00192218" TYPEGUESS="CLINTRIALGOV" --> [ClinicalTrials.gov] <!-- /HIGHWIRE -->.)<sup> </sup>[/FONT]
[FONT=arial, helvetica]<sup> </sup>[/FONT]

<hr>Children are important vectors for the spread of influenza within<sup> </sup>households and communities.<sup>1</sup><sup>,</sup><sup>2</sup><sup>,</sup><sup>3</sup><sup>,</sup><sup>4</sup><sup>,</sup><sup>5</sup><sup>,</sup><sup>6</sup> Focusing efforts for<sup> </sup>influenza vaccination on healthy children may therefore be an<sup> </sup>effective and practical method of reducing the burden of influenza<sup> </sup>in the community.<sup>7</sup><sup>,</sup><sup>8</sup><sup>,</sup><sup>9</sup><sup>,</sup><sup>10</sup> A recent pilot study demonstrated<sup> </sup>the feasibility of using trivalent, live attenuated influenza<sup> </sup>vaccine (FluMist, MedImmune) to vaccinate children in school<sup> </sup>and suggested there was a significant reduction in the rate<sup> </sup>of influenza-related outcomes in the households of children<sup> </sup>enrolled in the study.<sup>11</sup> The primary objective of our study<sup> </sup>was to assess the effect of a school-based vaccination program<sup> </sup>on the households of children attending the schools.<sup> </sup> [FONT=arial, helvetica][SIZE=+1]Methods[/SIZE][/FONT]
Control and Intervention Schools
We selected 24 public elementary schools in Maryland, Texas,<sup> </sup>and Minnesota and 4 parochial schools (kindergarten through<sup> </sup>eighth grade) in Washington state to participate in the study,<sup> </sup>to represent geographically and demographically diverse regions.<sup> </sup>Participating schools were grouped into clusters of two or three<sup> </sup>schools that were matched with respect to geographic characteristics<sup> </sup>and to students' ethnic background and socioeconomic status<sup> </sup>(according to the proportion of students receiving a subsidized<sup> </sup>lunch or tuition waiver). In each of the 11 clusters, one school<sup> </sup>was selected as the "intervention school" and was offered live<sup> </sup>attenuated influenza vaccine, and the other schools were designated<sup> </sup>as "control schools." The intervention school was selected randomly<sup> </sup>in seven of the clusters but designated by the school boards<sup> </sup>in the other four clusters (three in Maryland and one in Texas).<sup> </sup>School administrators in these four clusters would not accept<sup> </sup>a placebo-controlled or blinded study because of the disruption<sup> </sup>of class and staff time, with no benefit to pupils receiving<sup> </sup>placebo.<sup> </sup>
In the intervention schools, live attenuated influenza vaccine<sup> </sup>was offered at no charge to all healthy children 5 years or<sup> </sup>older in the fall of 2004. Members of households with children<sup> </sup>in either intervention schools or control schools could also<sup> </sup>receive influenza vaccination through their regular health care<sup> </sup>providers. The vaccine was administered according to its approved<sup> </sup>package insert.<sup>12</sup> Study nurses administered the 2004?2005<sup> </sup>formulation of the vaccine<sup>12</sup> intranasally to students during<sup> </sup>regular school hours. Children younger than 9 years who had<sup> </sup>never received the vaccine were offered a second dose 6 to 10<sup> </sup>weeks after the first dose. The institutional review board of<sup> </sup>each participating center approved the protocol. Written informed<sup> </sup>consent was obtained from the parents or guardians of all children<sup> </sup>who received the vaccine in the intervention schools. In addition,<sup> </sup>assent was obtained from the older children.<sup> </sup>
Community Influenza Surveillance
The week of peak influenza activity early in 2005 was predicted<sup> </sup>for each state on the basis of results of influenza cultures,<sup> </sup>antigen tests, or both from regional medical center laboratories<sup> </sup>and physician offices and on the basis of surveillance data<sup> </sup>from the Centers for Disease Control and Prevention (CDC), to<sup> </sup>trigger the distribution of the household survey. Retrospective<sup> </sup>review of the local data was used to identify periods of influenza<sup> </sup>activity for analysis of school-based attendance. At the end<sup> </sup>of the influenza season, three outbreak periods were defined<sup> </sup>in each of the four study sites: the peak influenza week (defined<sup> </sup>as the week with the highest number of positive influenza tests),<sup> </sup>the influenza outbreak period (defined as the weeks before and<sup> </sup>after the peak week that had the next highest number of positive<sup> </sup>influenza tests until the total number of positive influenza<sup> </sup>tests was 85% or more of the season's total positive tests),<sup> </sup>and the intense influenza outbreak period (defined as the 4-week<sup> </sup>period encompassing the peak week, giving the highest number<sup> </sup>of patients with positive results).<sup> </sup>
Household Questionnaire
Immediately after the predicted peak week, all households with<sup> </sup>children in intervention and control schools received a questionnaire<sup> </sup>(see the Supplementary Appendix, available with the full text<sup> </sup>of this article at www.nejm.org). The anonymous questionnaire<sup> </sup>included questions about the demographic characteristics and<sup> </sup>influenza-vaccination status of household members. It also included<sup> </sup>questions about outcomes among household members from the previous<sup> </sup>week related to influenza-like illness, which was defined as<sup> </sup>fever or respiratory illness that included any one or more of<sup> </sup>the following symptoms: runny nose, nasal congestion, sinus<sup> </sup>problems, earache, ear infection, cough, sore throat, muscle<sup> </sup>aches, chills, or wheezing. Questionnaires recorded the number<sup> </sup>of children and adults who had visited doctors or clinics, been<sup> </sup>hospitalized, taken medications, and missed days of school or<sup> </sup>work because of influenza-like illness.<sup> </sup>
School Attendance
We collected data on absenteeism for any cause for each week<sup> </sup>of the academic year from each school. Within intervention schools,<sup> </sup>rates were also collected separately for students who had received<sup> </sup>the vaccine.<sup> </sup>
Vaccine-Related Medical Outcomes
At the time of vaccination, parents of children who were about<sup> </sup>to receive the vaccine in an intervention school were questioned<sup> </sup>regarding the vaccinee's influenza-like symptoms, medication<sup> </sup>use, medically attended visits, and days of school lost, as<sup> </sup>well as paid days of work lost by a parent for the previous<sup> </sup>7 days. This survey was repeated for the 7 days after the vaccination.<sup> </sup>Parents were advised to report to study coordinators any serious<sup> </sup>adverse events that occurred within 42 days after vaccination.<sup> </sup>
Statistical Analysis
To assess the primary objectives, we compared outcomes related<sup> </sup>to influenza-like illness of members of all households with<sup> </sup>children in intervention schools with those of households with<sup> </sup>children in control schools with respect to the rate of each<sup> </sup>of the outcomes collected in the questionnaire. We calculated<sup> </sup>these rates by determining the total number of events among<sup> </sup>household members (summing across households) and dividing by<sup> </sup>the total number of people in the households (also summing across<sup> </sup>households). To assess the statistical significance of observed<sup> </sup>differences and to control for differences in states and clusters,<sup> </sup>the data were analyzed with the use of linear mixed-effects<sup> </sup>regression models, using household-specific rates of each outcome<sup> </sup>as the dependent variables. The model included random effects<sup> </sup>for cluster and school and a fixed effect for state and intervention.<sup> </sup>
In an additional post hoc analysis, we compared households with<sup> </sup>children in elementary or middle school who received the vaccine<sup> </sup>with those with children who did not receive the vaccine across<sup> </sup>all outcomes, regardless of study-group assignment. The analytic<sup> </sup>approach was similar to that used for the primary objective.<sup> </sup>
A secondary objective was to assess the number of school absences<sup> </sup>with the use of administrative data from the schools. The change<sup> </sup>in absenteeism was calculated for each school between the weeks<sup> </sup>before influenza activity (September and October) and each predicted<sup> </sup>influenza outbreak period. These differences were used as dependent<sup> </sup>variables in a linear mixed-effects model, which included a<sup> </sup>random effect for the cluster and a fixed effect for the state.<sup> </sup>In intervention schools only, we calculated the difference in<sup> </sup>absentee rates between students who received the vaccine and<sup> </sup>students who did not receive the vaccine, by means of the paired<sup> </sup>t-test.<sup> </sup>
In an additional secondary analysis, we assessed the immediate<sup> </sup>effect of vaccination by comparing the responses to the survey<sup> </sup>administered at the time of vaccination with the responses provided<sup> </sup>7 days later with respect to recent symptoms, medical care,<sup> </sup>school absenteeism, and workdays lost. The statistical significance<sup> </sup>of observed differences was assessed with the use of a generalized-estimating-equation<sup> </sup>approach<sup>13</sup> to account for the correlation between repeated observations<sup> </sup>from the same person.<sup> </sup>
The original study design was proposed by the principal academic<sup> </sup>investigator and refined with input from the other authors (see<sup> </sup>the Supplementary Appendix for the contributions of specific<sup> </sup>authors). This study was sponsored by MedImmune. One of the<sup> </sup>investigators was employed by MedImmune at the time of the study<sup> </sup>and participated in the writing of the manuscript. The authors<sup> </sup>had complete and unfettered access to the data and vouch for<sup> </sup>the veracity and completeness of the data and analyses.<sup> </sup>
[FONT=arial, helvetica][SIZE=+1]Results[/SIZE][/FONT]
Study Schools
The intervention and control schools had similar characteristics<sup> </sup>(Table 1), including the number of students enrolled, the number<sup> </sup>of households, historical rates of absenteeism, ethnic background,<sup> </sup>and socioeconomic level.<sup> </sup>
<!-- null --> <table cellpadding="0" cellspacing="0"><tbody><tr bgcolor="#e8e8d1"><td><table cellpadding="2" cellspacing="2"><tbody><tr bgcolor="#e8e8d1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]

</nobr> </td><td align="left" valign="top"> Table 1. Demographic Characteristics of Students and Their Households.
</td></tr></tbody></table></td></tr></tbody></table>
Vaccine Recipients
A total of 2717 of 5840 students (47%) in intervention schools<sup> </sup>received the vaccine after parental consent (range, 30 to 56%).<sup> </sup>Of the 1535 eligible students, 95% received a second dose. Of<sup> </sup>the vaccinated students, 73% had received no previous influenza<sup> </sup>vaccination. The average age of vaccinated students was 7.9<sup> </sup>years (range, 5 to 14). The ethnic background of vaccinated<sup> </sup>students was similar to that of the overall population of the<sup> </sup>intervention school.<sup> </sup>
Identification of Peak Influenza Week
The peak influenza week was predicted correctly at two sites<sup> </sup>and was within 2 to 4 weeks at the other sites, as determined<sup> </sup>by retrospective surveillance data (Figure 1). Of the positive<sup> </sup>specimens obtained, 75% tested positive for influenza A and<sup> </sup>25% for influenza B. Nationally, the CDC reported predominantly<sup> </sup>influenza A (H3N2) isolates, the majority of which were A/California/7/2004,<sup> </sup>a drifted strain that was antigenically distinct from the influenza<sup> </sup>A (H3N2) strain in the vaccine.<sup>14</sup><sup> </sup>
<!-- null --> <table cellpadding="0" cellspacing="0"><tbody><tr bgcolor="#e8e8d1"><td><table cellpadding="2" cellspacing="2"><tbody><tr bgcolor="#e8e8d1"><td align="center" bgcolor="#ffffff" valign="top">
View larger version (31K):
<nobr>[in this window]
[in a new window]

</nobr> </td><td align="left" valign="top"> Figure 1. Relationship between Number of Positive Influenza Tests and School Absentee Rates in Intervention Schools and Control Schools during Key Periods of Influenza Outbreaks in Washington (Panel A), Minnesota (Panel B), Texas (Panel C), and Maryland (Panel D) in 2005, as Compared with Baseline Measures. Baseline measures of absentee rates, which were obtained during an 8-week period in September and October 2004, are shown on the far left side of each panel, with numbers on the x axis indicating weeks of the year. The reference week of the questionnaire in early 2005 is indicated as a red number on the x axis in each panel. The peak week was defined as the week with the highest number of positive influenza tests. The influenza outbreak period was defined as the weeks before and after the peak week that had the next highest number of positive influenza tests until the total number of positive influenza tests was 85% or more of the season's total positive tests. The intense influenza outbreak period was defined as the 4-week period encompassing the peak week, giving the highest number of patients with positive results. CDC denotes Centers for Disease Control and Prevention.

</td></tr></tbody></table></td></tr></tbody></table>
Primary Outcomes
Questionnaires were returned by 77% of households with children<sup> </sup>in intervention schools and by 83% of households with children<sup> </sup>in control schools (Table 1). The number of reported episodes<sup> </sup>of influenza-like symptoms during the predicted peak influenza<sup> </sup>week was significantly lower in households with children in<sup> </sup>intervention schools than in households with children in control<sup> </sup>schools (Table 2). Reported rates of illness reflected rates<sup> </sup>for the entire household, which should not be confused with<sup> </sup>incidence rates based on reports of symptoms of individual household<sup> </sup>members. The number of reported episodes of fever plus cough<sup> </sup>or sore throat in children and adults in households with children<sup> </sup>in intervention schools was significantly lower than that in<sup> </sup>households with children in control schools (P<0.001 for<sup> </sup>comparisons of both children and adults in each group). The<sup> </sup>use of prescription, over-the-counter, and herbal medications<sup> </sup>for influenza-like illness was significantly lower in households<sup> </sup>with children in intervention schools than in households with<sup> </sup>children in control schools (P<0.001), as was the use of<sup> </sup>humidifiers (P=0.001).<sup> </sup>
<!-- null --> <table cellpadding="0" cellspacing="0"><tbody><tr bgcolor="#e8e8d1"><td><table cellpadding="2" cellspacing="2"><tbody><tr bgcolor="#e8e8d1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]

</nobr> </td><td align="left" valign="top"> Table 2. Primary Analysis of Rates of Reported Use of Health Care and Medication, Missed Workdays, and School Absences Owing to Fever or Influenza-like Illness during the Peak Influenza Week, as Reported on the Household Questionnaire.
</td></tr></tbody></table></td></tr></tbody></table>
As compared with children in control-school households, children<sup> </sup>in intervention-school households had fewer visits to doctors<sup> </sup>or clinics for influenza-like illness (P<0.001), and adults<sup> </sup>in these households had a trend toward fewer such visits (P=0.06).<sup> </sup>The rates of emergency-room visits did not differ significantly<sup> </sup>between the groups. Members of intervention-school households<sup> </sup>(both children and adults) had higher rates of hospitalization<sup> </sup>per 100 persons than did those in control-school households<sup> </sup>(0.27 and 0.10 for children, respectively; P=0.03; and 0.20<sup> </sup>and 0.13 for adults, respectively; P=0.05). However, the post<sup> </sup>hoc analyses comparing households with children who were vaccinated<sup> </sup>with those with children who were not vaccinated did not reveal<sup> </sup>a statistically significant difference in the number of hospitalizations<sup> </sup>for either children (0.20 per 100 persons for the vaccinated<sup> </sup>group vs. 0.10 per 100 persons for the unvaccinated group) or<sup> </sup>adults (0.15 per 100 persons for the vaccinated group vs. 0.15<sup> </sup>per 100 persons for the unvaccinated group). Hospitalizations<sup> </sup>were reported at every site except Seattle (see the Supplementary Appendix).<sup> </sup>
As compared with households with children in control schools,<sup> </sup>households with children in intervention schools reported significantly<sup> </sup>lower absentee rates for influenza-like illness among students<sup> </sup>in elementary school (P<0.001) and high school (P=0.03) and<sup> </sup>significantly fewer workdays that were missed by parents to<sup> </sup>care for their own, or someone else's, influenza-like illness<sup> </sup>(P=0.04).<sup> </sup>
Although 4 of the 11 intervention schools were not selected<sup> </sup>randomly, similar results were obtained when the analysis of<sup> </sup>data from the questionnaires was restricted to the randomized<sup> </sup>schools.<sup> </sup>
Prespecified Secondary Analyses
[FONT=arial, helvetica]School Reports of Absenteeism[/FONT]
The change in absenteeism for any reason from baseline to the<sup> </sup>time of the defined influenza outbreak periods did not differ<sup> </sup>significantly between the two groups (Table 3). Both intervention<sup> </sup>and control schools had increases in the rates of overall absenteeism<sup> </sup>during the influenza outbreak (Figure 1). Within intervention<sup> </sup>schools, unvaccinated students had a significantly greater increase<sup> </sup>in absentee rates over baseline than did vaccinated students<sup> </sup>for the predicted peak week (P=0.002), the intense influenza<sup> </sup>outbreak period (P=0.01), and the influenza outbreak period<sup> </sup>(P=0.006).<sup> </sup>
<!-- null --> <table cellpadding="0" cellspacing="0"><tbody><tr bgcolor="#e8e8d1"><td><table cellpadding="2" cellspacing="2"><tbody><tr bgcolor="#e8e8d1"><td align="center" bgcolor="#ffffff" valign="top"> View this table:
<nobr>[in this window]
[in a new window]

</nobr> </td><td align="left" valign="top"> Table 3. School-Reported Rates of Student Absenteeism for Any Reason, as Compared with Baseline.
</td></tr></tbody></table></td></tr></tbody></table>
[FONT=arial, helvetica]Safety[/FONT]
Results from surveys taken both before and after the administration<sup> </sup>of the vaccine were consistent with previous experience with<sup> </sup>live attenuated influenza vaccine<sup>12</sup> (Table 2 of the Supplementary Appendix).<sup> </sup>In surveys taken after vaccination, students had significantly<sup> </sup>elevated rates of symptoms of influenza-like illness (with the<sup> </sup>exception of wheezing) and use of nonprescription medicines<sup> </sup>and humidifiers than in surveys taken before vaccination. Vaccinated<sup> </sup>students had no significant increases in the use of prescription<sup> </sup>medications, visits to doctors or clinics, or missed days of<sup> </sup>school or work. No hospitalizations were reported among vaccinees<sup> </sup>in the first 7 days after vaccination. Four serious adverse<sup> </sup>events were noted in four students within 42 days after receiving<sup> </sup>the vaccine. These events included an episode of wheezing, shortness<sup> </sup>of breath, cough, and bronchospasm 4 days after vaccination<sup> </sup>in a 7-year-old, which was judged by an unblinded investigator<sup> </sup>as possibly related to the vaccine; the episode did not result<sup> </sup>in hospitalization. The other three events were judged either<sup> </sup>as not related or as probably not related to the vaccine by<sup> </sup>investigators who were aware of study-group assignments. These<sup> </sup>events included sore throat, nausea and vomiting, and fever<sup> </sup>with an elevated white-cell count 16 days after vaccination<sup> </sup>in a 7-year-old; gastroenteritis 1 day after vaccination in<sup> </sup>a 6-year-old; and an asthmatic exacerbation 36 days after vaccination<sup> </sup>in a 9-year-old. All events resolved completely.<sup> </sup>
[FONT=arial, helvetica][SIZE=+1]Discussion[/SIZE][/FONT]
This school-based vaccination intervention resulted in a reduction<sup> </sup>in influenza-related outcomes in household members of children<sup> </sup>attending intervention schools ? a finding that was consistent<sup> </sup>with the results from an earlier pilot study.<sup>11</sup> Unlike traditional<sup> </sup>vaccine trials, this study was designed to compare the effect<sup> </sup>of school-based vaccination on schoolchildren and their household<sup> </sup>members regardless of the vaccination status of individual students.<sup> </sup>For this reason, the primary, prospectively defined analysis,<sup> </sup>which compared results in the intervention schools with those<sup> </sup>in the control schools (i.e., analysis by the unit of randomization),<sup> </sup>was the most appropriate measure. By comparing all children<sup> </sup>in control schools with all children in intervention schools<sup> </sup>(including those not vaccinated), we avoided potential confounding<sup> </sup>owing to differences between children who chose to be vaccinated<sup> </sup>and those who did not choose to be vaccinated. Children who<sup> </sup>did not receive the vaccine included those whose underlying<sup> </sup>medical conditions put them at risk for influenza-related complications.<sup> </sup>
The safety profile of live attenuated influenza vaccine in this<sup> </sup>study reveals a modest but statistically significant increase<sup> </sup>in influenza-like symptoms and the use of nonprescription drugs<sup> </sup>after vaccination. However, these symptoms were probably mild<sup> </sup>because there were no significant increases in the use of prescription<sup> </sup>medications, visits to doctors or clinics, or school days or<sup> </sup>workdays lost by household members. There also was no increase<sup> </sup>in episodes of one of the most serious symptoms ? wheezing.<sup> </sup>However, in accordance with the prescribing information for<sup> </sup>the vaccine, children with asthma were not knowingly vaccinated.<sup> </sup>
For feasibility reasons, our study was not placebo-controlled<sup> </sup>? a major limitation. Our primary outcome analysis relied<sup> </sup>on the anonymous household questionnaire. This questionnaire<sup> </sup>was more susceptible to bias than were the school-based absentee<sup> </sup>data, which were essentially blinded. The bias in responses<sup> </sup>to the questionnaire would probably be strongest in households<sup> </sup>with children in intervention schools who received the vaccine.<sup> </sup>The temporal separation between the vaccination effort in the<sup> </sup>fall of 2004 and the distribution of the questionnaires in February<sup> </sup>2005 should have reduced this type of response bias.<sup> </sup>
In the secondary analysis, the school-based data on absenteeism<sup> </sup>did not confirm the differences observed in school absentee<sup> </sup>rates from data on the household questionnaires. Although the<sup> </sup>school-based data on absenteeism may be less subject to parental<sup> </sup>recall or selection bias than are the household data, the data<sup> </sup>from the two sources are not directly comparable. The effects<sup> </sup>of an influenza vaccination program on absenteeism will be influenced<sup> </sup>by the percentage of the measured absenteeism owing to influenza,<sup> </sup>and the direct and indirect effects of the intervention. Although<sup> </sup>the questionnaire data included absences owing to influenza-like<sup> </sup>symptoms, the school-based attendance data included absences<sup> </sup>for any reason, thus possibly "diluting" the effects of influenza.<sup> </sup>In addition, the "direct" effects of the intervention on the<sup> </sup>outcome may have differed and would have depended on the relative<sup> </sup>percentage of vaccinees within a household or school. Finally,<sup> </sup>at the vaccination rates achieved in this study, the effects<sup> </sup>of indirect protection from influenza at the community level<sup> </sup>(herd immunity) may have occurred at the household level, but<sup> </sup>not at the school level. Although the precise reasons for the<sup> </sup>differences in results are not known, the public health implication<sup> </sup>is that vaccination of elementary schoolchildren may have an<sup> </sup>indirect effect on the occurrence of influenza-like illness<sup> </sup>within their own households.<sup> </sup>
The strength of this school-based intervention study is that<sup> </sup>it represents a population-level intervention. Even though fewer<sup> </sup>than half the children were vaccinated, important benefits were<sup> </sup>observed. We did not systematically collect information on reasons<sup> </sup>why families chose not to participate in the vaccination program.<sup> </sup>Nonetheless, the similarity of the populations of students and<sup> </sup>households is demonstrated by the close match in the demographic<sup> </sup>composition of the control and intervention schools. Sensitivity<sup> </sup>analysis of the questionnaire data did not reveal any notable<sup> </sup>differences in results between clusters in which the intervention<sup> </sup>school was or was not selected randomly. Community influenza<sup> </sup>surveillance allowed us to predict a week with high influenza<sup> </sup>activity during which household questionnaires could be distributed,<sup> </sup>which should have enhanced the specificity of outcomes related<sup> </sup>to influenza-like illness. In addition, surveillance allowed<sup> </sup>the precise delineation of influenza activity in the community<sup> </sup>retrospectively. However, the lack of culture-confirmed end<sup> </sup>points may have resulted in an underestimation of effectiveness,<sup> </sup>because measurement of nonspecific outcomes tends to underestimate<sup> </sup>effectiveness.<sup>15</sup><sup> </sup>
The results of our primary analysis of data from questionnaires<sup> </sup>showed an increased rate of hospitalization for influenza-like<sup> </sup>illness among households with children in intervention schools,<sup> </sup>as compared with households with children in control schools.<sup> </sup>These data are contrary to other responses on the questionnaire.<sup> </sup>A post hoc analysis comparing households with vaccinated children<sup> </sup>and those with unvaccinated children indicated no significant<sup> </sup>difference in the rates of hospitalization in the two groups.<sup> </sup>This finding suggests that vaccination within the household<sup> </sup>was not the reason for the reported increased hospitalization<sup> </sup>for either children or adults. The post hoc analysis suggests<sup> </sup>that the results of the primary analysis of hospitalization<sup> </sup>rates are not robust. The questionnaire was not optimally designed<sup> </sup>to measure or characterize infrequent events, such as hospitalization,<sup> </sup>that we observed in this study. Nonetheless, it is difficult<sup> </sup>for us to understand why household members from intervention<sup> </sup>schools had an increased rate of hospitalization.<sup> </sup>
Previous studies have revealed reductions of various influenza-related<sup> </sup>outcomes in households or communities from interventions such<sup> </sup>as influenza vaccination of schoolchildren, prophylaxis with<sup> </sup>rimantadine, or the closing of schools during influenza outbreaks.<sup>8</sup><sup>,</sup><sup>16</sup><sup>,</sup><sup>17</sup><sup> </sup>A recent study conducted in Texas showed that herd immunity<sup> </sup>was associated with the use of live attenuated influenza vaccine<sup> </sup>in children.<sup>18</sup> Our multicenter study extends these observations<sup> </sup>and demonstrates that school-based immunization against influenza<sup> </sup>directly and indirectly reduces outcomes related to influenza-like<sup> </sup>illness.<sup> </sup>
<sup> </sup>
<sup> </sup>
[SIZE=-1]Supported by MedImmune.<sup> </sup>[/SIZE]
[SIZE=-1]Dr. King reports receiving grant support from Ross and MedImmune;<sup> </sup>Dr. Gaglani, consulting and lecture fees and grant support from<sup> </sup>MedImmune; Drs. Moore, Magder, McClure, and Rubin, grant support<sup> </sup>from MedImmune; Dr. Englund, consulting fees from Sanofi Pasteur,<sup> </sup>MedImmune, and Chiron, lecture fees from Sanofi Pasteur, and<sup> </sup>grant support from MedImmune and Sanofi Pasteur; and Dr. Neuzil,<sup> </sup>lecture fees and grant support from MedImmune. Dr. Stoddard<sup> </sup>reports being employed by MedImmune at the time the study was<sup> </sup>conducted. No other potential conflict of interest relevant<sup> </sup>to this article was reported.<sup> </sup>[/SIZE]
[SIZE=-1]We thank the study's medical staff, the school and school district<sup> </sup>personnel, and the viral surveillance personnel, including Ginny<sup> </sup>E. Cummings, Bernard X. Readmond, Alice Readmond, Elizabeth<sup> </sup>Ruff, Stuart Coles, Parita Patel, Michael Kirkpatrick, Helen<sup> </sup>Smith, Marcia Batista, Wendy Plank, Pamela Singer, Angela Boseman,<sup> </sup>Richard A. Venezia, Cynthia Little, Charles Ecker, Mark Vigliotti,<sup> </sup>Cynthia McCabe, Mary Stong, Tammy Richards, Robert Mitchell,<sup> </sup>Joseph Dorsey, Patricia Heacock, Martin Tierney, Richard Huss,<sup> </sup>Margaret Hoffmaster, John Lehigh, Paul Feinerman, Kevin Seymour,<sup> </sup>Joan Rambeck, Maria Gonzales, Jill Ruder, Janice Springer, Patricia<sup> </sup>Kirkpatrick, Rebecca L. Adams, Erlene Fritz, Linda Mason, Susan<sup> </sup>Fergus, Jim Hawkins, Charles Patterson, Barbara Adams, Jeff<sup> </sup>Heckathorn, Sue Cummings, Lucille Husung, Debra Burch, Barbara<sup> </sup>Allen, Julie Laguire, and Regina Rostomily. We also thank the<sup> </sup>children and parents who participated in this study; Mary Ann<sup> </sup>Russo and Caroleen Becker, for their operational support; Emily<sup> </sup>Reisner, for her technical support; Leiya Han, for her statistical<sup> </sup>support; and Ira Longini, Pedro Piedra, W. Paul Glezen, Shelah<sup> </sup>Leader, Kimmie McLaurin, and Kathleen Coelingh, for their contributions<sup> </sup>to the study concept and their careful review of the manuscript.<sup> </sup>[/SIZE]

[FONT=arial, helvetica][SIZE=+1]Source Information[/SIZE][/FONT]
[SIZE=-1] From the University of Maryland, Baltimore (J.C.K., L.M., J.D.R.); MedImmune, Gaithersburg, MD (J.J.S.); Scott and White Clinic, Texas A&M University, Temple (M.J.G.); University of Minnesota, Minneapolis (K.A.M., E.M.); and University of Washington, Seattle (J.A.E., K.N.). [/SIZE]
[SIZE=-1]Address reprint requests to Dr. King at the Department of Pediatrics, University of Maryland School of Medicine, 737 W. Lombard St., Baltimore, MD 21201, or at jking@peds.umaryland.edu<script type="text/javascript"><!-- var u = "jking", d = "peds.umaryland.edu"; document.getElementById("em0").innerHTML = '<a href="mailto:' + u + '@' + d + '">' + u + '@' + d + '<\/a>'//--></script>.[/SIZE]
[FONT=arial, helvetica][SIZE=+1]References[/SIZE][/FONT]
  1. <!-- null -->
  2. Monto AS, Sullivan KM. Acute respiratory illness in the community: frequency of illness and the agents involved. Epidemiol Infect 1993;110:145-160.<!-- HIGHWIRE ID="355:24:2523:1" --> [ISI][Medline]<!-- /HIGHWIRE --><!-- null -->
  3. Fox JP, Hall CE, Cooney MK, Foy HM. Influenzavirus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol 1982;116:212-227.<!-- HIGHWIRE ID="355:24:2523:2" --> <nobr>[Free Full Text]</nobr><!-- /HIGHWIRE --><!-- null -->
  4. Foy HM, Cooney MK, Hall C, Malmgren J, Fox JP. Case-to-case intervals of rhinovirus and influenza virus infections in households. J Infect Dis 1988;157:180-182.<!-- HIGHWIRE ID="355:24:2523:3" --> [ISI][Medline]<!-- /HIGHWIRE --><!-- null -->
  5. Long CE, Hall CB, Cunningham CK, et al. Influenza surveillance in community-dwelling elderly compared with children. Arch Fam Med 1997;6:459-465.<!-- HIGHWIRE ID="355:24:2523:4" --> [Abstract]<!-- /HIGHWIRE --><!-- null -->
  6. Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 2002;156:986-991.<!-- HIGHWIRE ID="355:24:2523:5" --> <nobr>[Free Full Text]</nobr><!-- /HIGHWIRE --><!-- null -->
  7. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 1978;298:587-592.<!-- HIGHWIRE ID="355:24:2523:6" --> [Abstract]<!-- /HIGHWIRE --><!-- null -->
  8. Longini IM Jr, Halloran ME. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 2005;161:303-306.<!-- HIGHWIRE ID="355:24:2523:7" --> <nobr>[Free Full Text]</nobr><!-- /HIGHWIRE --><!-- null -->
  9. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis 1970;122:16-25.<!-- HIGHWIRE ID="355:24:2523:8" --> [ISI][Medline]<!-- /HIGHWIRE --><!-- null -->
  10. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001;344:889-896.<!-- HIGHWIRE ID="355:24:2523:9" --> <nobr>[Free Full Text]</nobr><!-- /HIGHWIRE --><!-- null -->
  11. Weycker D, Edelsberg J, Halloran ME, et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine 2005;23:1284-1293.<!-- HIGHWIRE ID="355:24:2523:10" --> [CrossRef][ISI][Medline]<!-- /HIGHWIRE --><!-- null -->
  12. King JC Jr, Cummings GE, Stoddard J, et al. A pilot study of the effectiveness of a school-based influenza vaccination program. Pediatrics 2005;116:e868-e873.<!-- HIGHWIRE ID="355:24:2523:11" --> <nobr>[Free Full Text]</nobr><!-- /HIGHWIRE --><!-- null -->
  13. FluMist (influenza virus vaccine live, intranasal): full prescribing information. Gaithersburg, MD: MedImmune Vaccines, 2004 (package insert).<!-- HIGHWIRE ID="355:24:2523:12" --><!-- /HIGHWIRE --><!-- null -->
  14. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130.<!-- HIGHWIRE ID="355:24:2523:13" --> [CrossRef][ISI][Medline]<!-- /HIGHWIRE --><!-- null -->
  15. Update: influenza activity -- United States, 2004-05 season. MMWR Morb Mortal Wkly Rep 2005;54:328-331.<!-- HIGHWIRE ID="355:24:2523:14" --> [Medline]<!-- /HIGHWIRE --><!-- null -->
  16. Halloran ME, Longini IM Jr, Gaglani MJ, et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol 2003;158:305-311.<!-- HIGHWIRE ID="355:24:2523:15" --> <nobr>[Free Full Text]</nobr><!-- /HIGHWIRE --><!-- null -->
  17. Clover RD, Crawford SA, Abell TD, Ramsey CN Jr, Glezen WP, Couch RB. Effectiveness of rimantadine prophylaxis of children within families. Am J Dis Child 1986;140:706-709.<!-- HIGHWIRE ID="355:24:2523:16" --> [Abstract]<!-- /HIGHWIRE --><!-- null -->
  18. Heymann A, Chodick G, Reichman B, Kokia E, Laufer J. Influence of school closure on the incidence of viral respiratory diseases among children and on health care utilization. Pediatr Infect Dis J 2004;23:675-677.<!-- HIGHWIRE ID="355:24:2523:17" --> [ISI][Medline]<!-- /HIGHWIRE --><!-- null -->
  19. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005;23:1540-1548.<!-- HIGHWIRE ID="355:24:2523:18" --> [CrossRef][ISI][Medline]<!-- /HIGHWIRE -->
 
Back
Top